International Niemann–Pick Disease Alliance
The webinar will provide an opportunity to hear from Mallinckrodt Pharmaceuticals regarding their recent announcement, which has raised many questions and concerns about the future of adrabetadex for NPC-1.
Mallinckrodt has indicated that there will be a 6-9 month transition period during which those enrolled in the trial will be transitioned to an Expanded Access Programme (EAP). However, access to the EAP and the process for transition will vary from country to country, due to differences in regulatory requirements and health care systems.
The webinar is open to NPC patients and their family members and will feature representatives of Mallinckrodt Pharmaceuticals and Professor Elizabeth Berry-Kravis of Rush University Medical Centre.
Please click the link below to join the webinar: